LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion). The sales forecast comprises anti-clottin…
Posted: October 1st, 2012 | Company/topic: Novartis
Website: News
Novartis ($NVS) won European approval for its new COPD treatment Seebri Breezhaler, with potential peak sales of about $500 million. The Swiss drugmaker expects to launch by year's end. Report…
* Peak sales of Afinitor seen at $2.2 bln by 2017 - analyst…
Quintiles has introduced Allume, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic…
